ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Meeting News

SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC

Haleigh Behrman
on: July 08, 2025In: Evolving Standards of Care, Meeting News, Society News
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC

Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more


IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC

Haleigh Behrman
on: July 08, 2025In: Evolving Standards of Care, Meeting News, Society News
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC

The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations. Read more

Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS

Joy Curzio
on: June 24, 2025In: Evolving Standards of Care, Meeting News, Society News
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS

Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more

A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC

Haleigh Behrman
on: June 24, 2025In: Evolving Standards of Care, Meeting News, Society News
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC

Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more

Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC

Haleigh Behrman
on: June 10, 2025In: Meeting News, Society News
Lurbinectedin and Atezolizumab Combo Demonstrates Survival Benefit in ES-SCLC

Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting. Read more

Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC

Haleigh Behrman
on: June 10, 2025In: Meeting News, Society News
Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC

Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. Read more

Overcoming Resistance Remains a Challenge in Targeting KRAS

Haleigh Behrman
on: May 27, 2025In: Evolving Standards of Care, Meeting News, Names & News, Society News
Overcoming Resistance Remains a Challenge in Targeting KRAS

Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more

Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy

Haleigh Behrman
on: May 13, 2025In: Meeting News, Society News
Beamion LUNG-01 Trial Results Support Zongertinib’s Potential as a First-Line Therapy

Dr. John V. Heymach says the latest findings suggest zongertinib may address an unmet need for patients with HER2-mutant NSCLC. Read more

Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC

Nathan Pettengill
on: May 13, 2025In: Meeting News, Society News
Results From the AENEAS2 Trial Point to a New Frontline Treatment Option for NSCLC

Research team led by Dr. Shun Lu presents aumolertinib with chemotherapy as an additional first-line treatment option during the 2025 AACR Annual Meeting. Read more

A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going

Haleigh Behrman
on: May 13, 2025In: Meeting News, Society News
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going

Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC. Read more

1234›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy